Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

Authors: Jing Wang, Renbing Jia, Yidan Zhang, Xiaofang Xu, Xin Song, Yixiong Zhou, He Zhang, Shengfang Ge, Xianqun Fan

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Gemcitabine (GEM), a new cytotoxic agent, was shown to be effective against uveal melanoma (UM) which is noted for its resistance to chemotherapy. In this study, we found the different sensitivities to GEM in UM cell lines and identified apoptotic cell death as the cause of GEM cytotoxicity. Both UM cell lines showed an increase in Bax protein levels and activation of cleaved Caspase 3. Additionally, SP6.5 cells showed a gradual increase in Bcl-2 expression over time, whereas VUP cells showed almost none. After interfering in the expression of Bcl-2, the sensitivity to GEM was obviously enhanced in SP6.5 cells. These results suggest that an increase in Bax plays a crucial role in apoptotic cell death induced by GEM in the absence of p53. Moreover, inhibition of Bcl-2 expression can efficiently enhance the cytotoxic effect of, and sensitivity to, GEM in UM cells.
Literature
1.
2.
Zoli W. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004;10(4):1500–7.PubMedCrossRef
3.
Ramanathan RK. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin Oncol. 1997;24:440–54.PubMed
4.
Yamagishi Y. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146–54.PubMedCrossRef
5.
Neale MH. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487–93.PubMedCentralPubMedCrossRef
6.
Schmittel A. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17(12):1826–9.PubMedCrossRef
7.
Atzpodien J. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol. 2008;62(4):685–8.PubMedCrossRef
8.
Ruiz van Haperen VW. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46:762–6.PubMedCrossRef
9.
Plunkett W. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.PubMed
10.
Chen M. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000;45(5):369–74.PubMedCrossRef
11.
Galmarini CM. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002;97(4):439–45.PubMedCrossRef
12.
Zhou Y. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res. 2010;23(5):661–74.PubMedCrossRef
13.
Cun B. Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA. Tumour Biol. 2013;34(3):1801–6.PubMedCrossRef
14.
Zhang Y. Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells. Int J Mol Sci. 2013;14(4):15092–104.PubMedCentralPubMedCrossRef
15.
Zhang H. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther. 2009;17(1):57–64.PubMedCrossRef
16.
Wang J. Differential expression of Mart-1 in human uveal melanoma cells. Mol Med Rep. 2011;4(5):799–803.PubMed
17.
Xu X. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011;38(5):1385–93.PubMed
18.
19.
Kastan MB. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15.PubMedCrossRef
20.
21.
Huang X. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br J Ophthalmol. 2012;96:1331–8.PubMedCrossRef
22.
Brady HJ. T cells from bax α transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J. 1996;15(6):1221–30.PubMed
23.
Oltvai Z. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–19.PubMedCrossRef
24.
Zhang J. Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3′-UTR microRNA. Int J Cancer. 2010;126(9):2229–39.PubMedCentralPubMed
25.
Chang GC. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004;502(3):169–83.PubMedCrossRef
26.
Yao Y. Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells. Oncol Lett. 2012;4(1):163–7.PubMedCentralPubMed
27.
Metadata
Title
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells
Authors
Jing Wang
Renbing Jia
Yidan Zhang
Xiaofang Xu
Xin Song
Yixiong Zhou
He Zhang
Shengfang Ge
Xianqun Fan
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1156-6

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis

Research Article

Association between IL-4 -590C>T polymorphism and gastric cancer risk

Research Article

Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53

Research Article

Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model

Research Article

Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway

Research Article

Epitope analysis and detection of human chorionic gonadotropin (hCG) variants by monoclonal antibodies and mass spectrometry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits